Summit Therapeutics Inc. (SMMT) 10-Year Financial Performance & Capital Metrics

SMMT •

HealthcareBiotechnologyVaccines and Infectious Disease

AboutSummit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.Show more

Revenue $0
EBITDA -$812M -4751.1%
Net Income -$1.08B -387.8%
EPS (Diluted) -1.44 -364.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -206.1% -117.2%
ROIC -163.41% -140485.6%
Debt/Equity 0.03 +70.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Expensive at 18.8x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-387.81%

EPS CAGR

10Y-

5Y-

3Y-

TTM-366.58%

ROCE

10Y Avg-57.37%

5Y Avg-58.31%

3Y Avg-57.88%

Latest-151.53%

Peer Comparison

Vaccines and Infectious Disease

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
NVAXNovavax, Inc.	1.67B	10.14	3.93	64.69%	39.19%
SCNIScinai Immunotherapeutics Ltd.	3.03B	0.89	0.15		401.83%	58.65%		0.21
TNXPTonix Pharmaceuticals Holding Corp.	142.05M	13.97	-0.08	29.94%	-9.63%	-42.93%		0.04
INOInovio Pharmaceuticals, Inc.	65.34M	1.81	-0.46	-73.83%	-592.82%	-115.42%		0.17
IVVDInvivyd, Inc.	362.35M	1.69	-1.18		-119.63%	-64.32%		0.02
SPROSpero Therapeutics, Inc.	122.2M	2.17	-1.71	-53.77%	-122.56%	-165.46%		0.09
AVIRAtea Pharmaceuticals, Inc.	365.63M	4.68	-2.34			-46.56%		0.00

Profit & Loss

	Jan 2017	Jan 2018	Jan 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	2.88M	17.5M	56.41M	611.87K	860K	1.81M	704.29K	0	0	0
Revenue Growth %	124.82%	507.47%	222.45%	-98.92%	40.55%	110.35%	-61.07%	-100%	-	-
Cost of Goods Sold+	0	97.67K	24.92K	155.4K	0	0	2.51M	2.05M	15.01M	108.36K
COGS % of Revenue	-	0.56%	0.04%	25.4%	-	-	356.95%	-	-	-
Gross Profit+	2.88M	17.4M	56.39M	476.62K	860K	1.81M	-1.81M	-2.05M	-15.01M	-108.36K
Gross Margin %	100%	99.45%	99.96%	77.9%	100%	100%	-256.99%	-	-	-
Gross Profit Growth %	-	504.1%	224.11%	-99.15%	80.44%	110.35%	-200.06%	-13.26%	-632.05%	99.28%
Operating Expenses+	33.95M	54.13M	47.69M	39.18M	53.19M	88M	64.28M	87.69M	211.3M	1.09B
OpEx % of Revenue	1178.65%	309.42%	84.53%	6403.63%	6185.35%	4864.29%	9127.28%	-	-	-
Selling, General & Admin	9.62M	13.71M	17.01M	9.3M	19.23M	23.61M	26.7M	30.27M	60.53M	556.75M
SG&A % of Revenue	334.03%	78.39%	30.16%	1519.76%	2236.28%	1305.2%	3791.03%	-	-	-
Research & Development	23.69M	41.01M	51.38M	39.18M	53.27M	85.35M	52M	59.47M	150.78M	537.67M
R&D % of Revenue	822.53%	234.39%	91.08%	6403.63%	6194.65%	4718.19%	7383.13%	-	-	-
Other Operating Expenses	639.98K	-743K	-14.41M	-18.84M	-13.49M	-20.97M	-5.95M	0	0	0
Operating Income+	-31.07M	-36.56M	5.39M	-22.62M	-53.19M	-86.19M	-59.63M	-89.74M	313K	-812.24M
Operating Margin %	-1078.65%	-208.97%	9.55%	-3697.51%	-6185.23%	-4764.29%	-8467.05%	-	-	-
Operating Income Growth %	-8.11%	-17.69%	114.74%	-519.82%	-135.12%	-62.03%	30.81%	-50.48%	100.35%	-259600.87%
EBITDA+	-30.99M	-36.21M	7.34M	-21.23M	-51.19M	-83.73M	-58.37M	-89.58M	17.46M	-812.13M
EBITDA Margin %	-1076.13%	-206.98%	13.01%	-3470.01%	-5952.33%	-4628.58%	-8287.72%	-	-	-
EBITDA Growth %	-8.11%	-16.84%	120.27%	-389.22%	-141.1%	-63.57%	30.29%	-53.47%	119.49%	-4751.1%
D&A (Non-Cash Add-back)	72.5K	348.2K	1.95M	1.39M	2M	2.46M	1.26M	155.32K	17.15M	108.36K
EBIT	-31.05M	-32.76M	9.7M	-22.62M	-52.66M	-88.36M	-74.38M	-69.61M	-230M	-801.23M
Net Interest Income+	-1.07M	2.7M	-615K	-36.18K	-251K	-242K	-2.89M	-6.06M	4.78M	11.5M
Interest Income	10K	4.38M	5K	4.34K	4K	178.95K	1.51M	10.4M	13.47M	11.5M
Interest Expense	1.08M	1.65M	620K	32.52K	255K	281K	4.4M	16.46M	8.69M	0
Other Income/Expense	-1.07M	1.91M	3.69M	-10.16M	206.94K	-2.42M	-6.69M	-526.14M	-221.63M	11.01M
Pretax Income+	-32.13M	-33.86M	9.08M	-28.41M	-52.91M	-88.6M	-78.78M	-615.87M	-221.31M	-801.23M
Pretax Margin %	-1115.73%	-193.53%	16.1%	-4642.8%	-6152.33%	-4897.84%	-11185.94%	-	-	-
Income Tax+	-5.42M	-5.33M	-1.79M	-4.52M	-213K	0	0	-946K	0	0
Effective Tax Rate %	66.51%	84.27%	108.69%	84.07%	99.6%	100%	100%	99.85%	100%	134.74%
Net Income+	-21.37M	-28.53M	9.87M	-23.88M	-52.7M	-88.6M	-78.78M	-614.93M	-221.31M	-1.08B
Net Margin %	-742.05%	-163.09%	17.5%	-3903.43%	-6127.56%	-4897.84%	-11185.94%	-	-	-
Net Income Growth %	12.19%	-33.51%	134.6%	-341.94%	-120.64%	-68.13%	11.08%	-680.54%	64.01%	-387.81%
Net Income (Continuing)	-26.71M	-20.16M	10.87M	-23.99M	-52.7M	-88.6M	-78.78M	-614.93M	-221.31M	-1.08B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.43	-0.15	0.11	-0.15	-0.76	-0.96	-0.38	-0.99	-0.31	-1.44
EPS Growth %	-4.88%	65.12%	173.33%	-236.36%	-406.67%	-26.32%	60.42%	-160.53%	68.69%	-364.52%
EPS (Basic)	-0.43	-0.16	0.11	-0.15	-0.76	-0.96	-0.41	-0.99	-0.31	-1.44
Diluted Shares Outstanding	61.55M	65.43M	86.14M	32.83M	69.52M	92.24M	193.34M	619.65M	718.54M	747.7M
Basic Shares Outstanding	61.55M	65.03M	86.14M	32.73M	69.52M	92.24M	193.34M	619.65M	718.54M	747.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jan 2017	Jan 2018	Jan 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	41.67M	50.8M	61.29M	62.11M	66.42M	97.31M	656.71M	189.71M	423.75M	720.3M
Cash & Short-Term Investments	35.08M	28.45M	35.23M	49.96M	66.42M	71.79M	348.61M	186.24M	412.35M	713.45M
Cash Only	35.08M	28.45M	35.23M	49.96M	66.42M	71.79M	348.61M	71.42M	104.86M	225.27M
Short-Term Investments	0	0	0	0	0	0	0	114.82M	307.49M	488.18M
Accounts Receivable	0	11.09M	7.95M	5.29M	10.19M	24.32M	6.12M	848K	557K	0
Days Sales Outstanding	-	231.31	51.41	3.16K	4.32K	4.91K	3.17K	-	-	-
Inventory	110.56K	0	0	2	-11.71M	7.16M	0	0	0	0
Days Inventory Outstanding	-	-	-	0	-	-	-	-	-	-
Other Current Assets	4.59M	15.78M	8.3M	6.86M	1.52M	1.2M	300.49M	181K	10.84M	6.85M
Total Non-Current Assets+	5.31M	25.58M	17.09M	13.34M	36.08M	16.06M	7.46M	13.24M	11.81M	30.88M
Property, Plant & Equipment	144.99K	1.15M	807.92K	1.2M	1.28M	3.48M	5.08M	6.06M	7.4M	21.68M
Fixed Asset Turnover	19.86x	15.28x	69.82x	0.51x	0.67x	0.52x	0.14x	-	-	-
Goodwill	829.97K	3.51M	2.38M	1.15M	2.03M	2.01M	1.8M	1.89M	1.86M	2M
Intangible Assets	4.34M	20.93M	13.91M	7.71M	11.52M	10.4M	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	3.27M	21.26M	170K	577K	5.28M	2.55M	7.21M
Total Assets+	46.98M	76.38M	78.39M	75.46M	102.5M	113.37M	664.17M	202.95M	435.56M	751.18M
Asset Turnover	0.06x	0.23x	0.72x	0.01x	0.01x	0.02x	0.00x	-	-	-
Asset Growth %	31.55%	62.58%	2.63%	-3.74%	35.84%	10.61%	485.82%	-69.44%	114.62%	72.46%
Total Current Liabilities+	13.62M	26.81M	16.88M	9.9M	19.89M	25.62M	38.78M	20.41M	41.73M	72.99M
Accounts Payable	1.13M	12.49M	5.8M	2.63M	6.14M	4.37M	355K	2.67M	4.64M	15.06M
Days Payables Outstanding	-	46.68K	84.95K	6.18K	-	-	51.54	474.86	112.76	50.73K
Short-Term Debt	0	0	0	632.64K	0	284.24K	19.77M	0	0	3.39M
Deferred Revenue (Current)	8.64M	-18.03M	0	1.17M	8.37M	7.94M	0	0	0	0
Other Current Liabilities	6.64M	20.04M	10.62M	2.45M	1.71M	5.31M	6.3M	9.5M	33.33M	54.54M
Current Ratio	3.06x	1.89x	3.63x	6.27x	3.34x	3.80x	16.93x	9.30x	10.15x	9.87x
Quick Ratio	3.05x	1.89x	3.63x	6.27x	3.93x	3.52x	16.93x	9.30x	10.15x	9.87x
Cash Conversion Cycle	-	-	-	-3.02K	-	-	-	-	-	-
Total Non-Current Liabilities+	37.73M	35.59M	5.71M	4.44M	3.15M	4.47M	498.73M	104.85M	5.08M	19.33M
Long-Term Debt	0	-17.21M	0	0	0	0	494.54M	100M	0	17.5M
Capital Lease Obligations	0	962K	0	318.56K	75K	1.25M	2.76M	3.29M	3.45M	12.99M
Deferred Tax Liabilities	706.22K	3.37M	2.2M	1.61M	0	0	0	0	0	0
Other Non-Current Liabilities	-39.87K	5.73M	3.28M	2.2M	2.51M	3.22M	1.43M	1.56M	1.63M	-11.63M
Total Liabilities	51.35M	62.4M	22.59M	14.34M	23.05M	30.09M	537.51M	125.26M	46.81M	92.32M
Total Debt+	0	0	0	699.64K	465K	2.78M	518.76M	106.1M	7.22M	20.89M
Net Debt	-35.08M	-28.45M	-35.23M	-49.26M	-65.95M	-69.01M	170.16M	34.67M	-97.64M	-204.38M
Debt / Equity	-	-	-	0.01x	0.01x	0.03x	4.10x	1.37x	0.02x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	0.41x	-
Net Debt / EBITDA	-	-	-4.80x	-	-	-	-	-	-5.59x	-
Interest Coverage	-28.84x	-22.18x	8.69x	-695.65x	-208.60x	-306.71x	-13.55x	-5.45x	0.04x	-
Total Equity+	-4.37M	13.98M	55.8M	61.12M	79.45M	83.28M	126.65M	77.69M	388.75M	658.86M
Equity Growth %	-114.51%	420.14%	299.18%	9.53%	30.01%	4.82%	52.07%	-38.66%	400.37%	69.48%
Book Value per Share	-0.07	0.21	0.65	1.86	1.14	0.90	0.66	0.13	0.54	0.88
Total Shareholders' Equity	-4.37M	13.98M	55.8M	61.12M	79.45M	83.28M	126.65M	77.69M	388.75M	658.86M
Common Stock	772.47K	1.04M	2.1M	3.47M	826K	980K	2.11M	7.02M	7.38M	7.75M
Retained Earnings	-92.21M	-114.51M	-99.8M	-97.61M	-214.74M	-299.55M	-378.33M	-993.26M	-1.21B	-2.29B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	25.74M	0	0	22.03M	-3.79M	-2.2M	-1.89M	-2.45M	-2.29M	-2.54M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jan 2017	Jan 2018	Jan 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	15.18M	-20.79M	-35.14M	-15.56M	-48.11M	-72.59M	-41.58M	-76.76M	-142.11M	-322.93M
Operating CF Margin %	526.93%	-118.84%	-62.3%	-2543.82%	-5594.3%	-4012.55%	-5904.06%	-	-	-
Operating CF Growth %	162.02%	-237.01%	-69.02%	55.71%	-209.1%	-50.87%	42.71%	-84.6%	-85.13%	-127.25%
Net Income	-32.13M	-15.42M	6.6M	-23.88M	-52.7M	-88.6M	-78.78M	-614.93M	-221.31M	-1.08B
Depreciation & Amortization	72.5K	348.2K	1.49M	1.39M	2M	2.46M	2.51M	2.05M	89K	-6.86M
Stock-Based Compensation	1.72M	2.27M	6.22M	542.05K	1.29M	9.47M	9.88M	14.11M	50.98M	732.42M
Deferred Taxes	4.66M	0	3	309.13K	583K	326K	0	0	0	0
Other Non-Cash Items	1.06M	3.47M	1.73M	5.12M	-385K	497K	14.12M	524.38M	12.66M	7.78M
Working Capital Changes	39.79M	-11.47M	-51.18M	955.98K	619K	-67K	8.62M	-2.37M	15.48M	23.32M
Change in Receivables	0	0	0	4.63M	212K	-1.14M	975K	4.53M	535K	0
Change in Inventory	0	0	0	-2	-6.61M	3.6M	0	0	0	0
Change in Payables	0	0	0	-997.71K	1.64M	-1.71M	-4.13M	2.26M	2.02M	11.36M
Cash from Investing+	-100K	-7.42M	-410.52K	-265.33K	-421K	-306K	-624K	-587.77M	-205.34M	-174.31M
Capital Expenditures	-110K	-678.01K	-163.94K	-265.33K	-421K	-306K	-624K	-128K	-139K	-657K
CapEx % of Revenue	3.82%	3.88%	0.29%	43.36%	48.95%	16.92%	88.6%	-	-	-
Acquisitions	0	-6.76M	-251.82K	-99.19K	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	10K	16.98K	5.25K	11.95K	0	0	-600	-474.79M	-15.01M	0
Cash from Financing+	516.23K	19.68M	43.85M	37.46M	50.55M	77.92M	620.24M	86.51M	381.23M	617.53M
Debt Issued (Net)	23K	-181.18K	-368.55K	0	0	0	520M	-24.69M	-100M	0
Equity Issued (Net)	0	1000K	1000K	0	1000K	1000K	0	1000K	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	493.23K	-7.05M	-1.21M	37.46M	551K	2.92M	100.24M	106.2M	3.33M	159.22M
Net Change in Cash	14.7M	-11.27M	8.86M	27.7M	2.58M	5.37M	576.82M	-577.18M	33.76M	120.39M
Free Cash Flow+	15.07M	-21.47M	-35.31M	-15.83M	-48.53M	-72.89M	-42.21M	-76.89M	-142.25M	-323.59M
FCF Margin %	523.11%	-122.72%	-62.59%	-2587.18%	-5643.26%	-4029.46%	-5992.66%	-	-	-
FCF Growth %	161.33%	-242.51%	-64.45%	55.16%	-206.58%	-50.2%	42.1%	-82.17%	-85%	-127.49%
FCF per Share	0.24	-0.33	-0.41	-0.48	-0.70	-0.79	-0.22	-0.12	-0.20	-0.43
FCF Conversion (FCF/Net Income)	-0.71x	0.73x	-3.56x	0.65x	0.91x	0.82x	0.53x	0.12x	0.64x	0.30x
Interest Paid	0	0	0	0	0	85K	0	10.65M	0	0
Taxes Paid	0	0	0	0	0	7K	0	52K	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-166.11%	-593.72%	28.3%	-40.86%	-74.98%	-108.89%	-75.05%	-601.85%	-94.9%	-206.1%
Return on Invested Capital (ROIC)	-	-	132.64%	-104.67%	-314.71%	-465.43%	-28.75%	-32.9%	0.12%	-163.41%
Gross Margin	100%	99.45%	99.96%	77.9%	100%	100%	-256.99%	-	-	-
Net Margin	-742.05%	-163.09%	17.5%	-3903.43%	-6127.56%	-4897.84%	-11185.94%	-	-	-
Debt / Equity	-	-	-	0.01x	0.01x	0.03x	4.10x	1.37x	0.02x	0.03x
Interest Coverage	-28.84x	-22.18x	8.69x	-695.65x	-208.60x	-306.71x	-13.55x	-5.45x	0.04x	-
FCF Conversion	-0.71x	0.73x	-3.56x	0.65x	0.91x	0.82x	0.53x	0.12x	0.64x	0.30x
Revenue Growth	124.82%	507.47%	222.45%	-98.92%	40.55%	110.35%	-61.07%	-100%	-	-

US Stock Screener

...

Summit Therapeutics Inc. (SMMT) 10-Year Financial Performance & Capital Metrics

SMMT •

HealthcareBiotechnologyVaccines and Infectious Disease

Revenue $0
EBITDA -$812M -4751.1%
Net Income -$1.08B -387.8%
EPS (Diluted) -1.44 -364.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -206.1% -117.2%
ROIC -163.41% -140485.6%
Debt/Equity 0.03 +70.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Expensive at 18.8x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-387.81%

EPS CAGR

10Y-

5Y-

3Y-

TTM-366.58%

ROCE

10Y Avg-57.37%

5Y Avg-58.31%

3Y Avg-57.88%

Latest-151.53%

Peer Comparison

Vaccines and Infectious Disease

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
NVAXNovavax, Inc.	1.67B	10.14	3.93	64.69%	39.19%
SCNIScinai Immunotherapeutics Ltd.	3.03B	0.89	0.15		401.83%	58.65%		0.21
TNXPTonix Pharmaceuticals Holding Corp.	142.05M	13.97	-0.08	29.94%	-9.63%	-42.93%		0.04
INOInovio Pharmaceuticals, Inc.	65.34M	1.81	-0.46	-73.83%	-592.82%	-115.42%		0.17
IVVDInvivyd, Inc.	362.35M	1.69	-1.18		-119.63%	-64.32%		0.02
SPROSpero Therapeutics, Inc.	122.2M	2.17	-1.71	-53.77%	-122.56%	-165.46%		0.09
AVIRAtea Pharmaceuticals, Inc.	365.63M	4.68	-2.34			-46.56%		0.00

Profit & Loss

	Jan 2017	Jan 2018	Jan 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	2.88M	17.5M	56.41M	611.87K	860K	1.81M	704.29K	0	0	0
Revenue Growth %	124.82%	507.47%	222.45%	-98.92%	40.55%	110.35%	-61.07%	-100%	-	-
Cost of Goods Sold+	0	97.67K	24.92K	155.4K	0	0	2.51M	2.05M	15.01M	108.36K
COGS % of Revenue	-	0.56%	0.04%	25.4%	-	-	356.95%	-	-	-
Gross Profit+	2.88M	17.4M	56.39M	476.62K	860K	1.81M	-1.81M	-2.05M	-15.01M	-108.36K
Gross Margin %	100%	99.45%	99.96%	77.9%	100%	100%	-256.99%	-	-	-
Gross Profit Growth %	-	504.1%	224.11%	-99.15%	80.44%	110.35%	-200.06%	-13.26%	-632.05%	99.28%
Operating Expenses+	33.95M	54.13M	47.69M	39.18M	53.19M	88M	64.28M	87.69M	211.3M	1.09B
OpEx % of Revenue	1178.65%	309.42%	84.53%	6403.63%	6185.35%	4864.29%	9127.28%	-	-	-
Selling, General & Admin	9.62M	13.71M	17.01M	9.3M	19.23M	23.61M	26.7M	30.27M	60.53M	556.75M
SG&A % of Revenue	334.03%	78.39%	30.16%	1519.76%	2236.28%	1305.2%	3791.03%	-	-	-
Research & Development	23.69M	41.01M	51.38M	39.18M	53.27M	85.35M	52M	59.47M	150.78M	537.67M
R&D % of Revenue	822.53%	234.39%	91.08%	6403.63%	6194.65%	4718.19%	7383.13%	-	-	-
Other Operating Expenses	639.98K	-743K	-14.41M	-18.84M	-13.49M	-20.97M	-5.95M	0	0	0
Operating Income+	-31.07M	-36.56M	5.39M	-22.62M	-53.19M	-86.19M	-59.63M	-89.74M	313K	-812.24M
Operating Margin %	-1078.65%	-208.97%	9.55%	-3697.51%	-6185.23%	-4764.29%	-8467.05%	-	-	-
Operating Income Growth %	-8.11%	-17.69%	114.74%	-519.82%	-135.12%	-62.03%	30.81%	-50.48%	100.35%	-259600.87%
EBITDA+	-30.99M	-36.21M	7.34M	-21.23M	-51.19M	-83.73M	-58.37M	-89.58M	17.46M	-812.13M
EBITDA Margin %	-1076.13%	-206.98%	13.01%	-3470.01%	-5952.33%	-4628.58%	-8287.72%	-	-	-
EBITDA Growth %	-8.11%	-16.84%	120.27%	-389.22%	-141.1%	-63.57%	30.29%	-53.47%	119.49%	-4751.1%
D&A (Non-Cash Add-back)	72.5K	348.2K	1.95M	1.39M	2M	2.46M	1.26M	155.32K	17.15M	108.36K
EBIT	-31.05M	-32.76M	9.7M	-22.62M	-52.66M	-88.36M	-74.38M	-69.61M	-230M	-801.23M
Net Interest Income+	-1.07M	2.7M	-615K	-36.18K	-251K	-242K	-2.89M	-6.06M	4.78M	11.5M
Interest Income	10K	4.38M	5K	4.34K	4K	178.95K	1.51M	10.4M	13.47M	11.5M
Interest Expense	1.08M	1.65M	620K	32.52K	255K	281K	4.4M	16.46M	8.69M	0
Other Income/Expense	-1.07M	1.91M	3.69M	-10.16M	206.94K	-2.42M	-6.69M	-526.14M	-221.63M	11.01M
Pretax Income+	-32.13M	-33.86M	9.08M	-28.41M	-52.91M	-88.6M	-78.78M	-615.87M	-221.31M	-801.23M
Pretax Margin %	-1115.73%	-193.53%	16.1%	-4642.8%	-6152.33%	-4897.84%	-11185.94%	-	-	-
Income Tax+	-5.42M	-5.33M	-1.79M	-4.52M	-213K	0	0	-946K	0	0
Effective Tax Rate %	66.51%	84.27%	108.69%	84.07%	99.6%	100%	100%	99.85%	100%	134.74%
Net Income+	-21.37M	-28.53M	9.87M	-23.88M	-52.7M	-88.6M	-78.78M	-614.93M	-221.31M	-1.08B
Net Margin %	-742.05%	-163.09%	17.5%	-3903.43%	-6127.56%	-4897.84%	-11185.94%	-	-	-
Net Income Growth %	12.19%	-33.51%	134.6%	-341.94%	-120.64%	-68.13%	11.08%	-680.54%	64.01%	-387.81%
Net Income (Continuing)	-26.71M	-20.16M	10.87M	-23.99M	-52.7M	-88.6M	-78.78M	-614.93M	-221.31M	-1.08B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.43	-0.15	0.11	-0.15	-0.76	-0.96	-0.38	-0.99	-0.31	-1.44
EPS Growth %	-4.88%	65.12%	173.33%	-236.36%	-406.67%	-26.32%	60.42%	-160.53%	68.69%	-364.52%
EPS (Basic)	-0.43	-0.16	0.11	-0.15	-0.76	-0.96	-0.41	-0.99	-0.31	-1.44
Diluted Shares Outstanding	61.55M	65.43M	86.14M	32.83M	69.52M	92.24M	193.34M	619.65M	718.54M	747.7M
Basic Shares Outstanding	61.55M	65.03M	86.14M	32.73M	69.52M	92.24M	193.34M	619.65M	718.54M	747.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jan 2017	Jan 2018	Jan 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	41.67M	50.8M	61.29M	62.11M	66.42M	97.31M	656.71M	189.71M	423.75M	720.3M
Cash & Short-Term Investments	35.08M	28.45M	35.23M	49.96M	66.42M	71.79M	348.61M	186.24M	412.35M	713.45M
Cash Only	35.08M	28.45M	35.23M	49.96M	66.42M	71.79M	348.61M	71.42M	104.86M	225.27M
Short-Term Investments	0	0	0	0	0	0	0	114.82M	307.49M	488.18M
Accounts Receivable	0	11.09M	7.95M	5.29M	10.19M	24.32M	6.12M	848K	557K	0
Days Sales Outstanding	-	231.31	51.41	3.16K	4.32K	4.91K	3.17K	-	-	-
Inventory	110.56K	0	0	2	-11.71M	7.16M	0	0	0	0
Days Inventory Outstanding	-	-	-	0	-	-	-	-	-	-
Other Current Assets	4.59M	15.78M	8.3M	6.86M	1.52M	1.2M	300.49M	181K	10.84M	6.85M
Total Non-Current Assets+	5.31M	25.58M	17.09M	13.34M	36.08M	16.06M	7.46M	13.24M	11.81M	30.88M
Property, Plant & Equipment	144.99K	1.15M	807.92K	1.2M	1.28M	3.48M	5.08M	6.06M	7.4M	21.68M
Fixed Asset Turnover	19.86x	15.28x	69.82x	0.51x	0.67x	0.52x	0.14x	-	-	-
Goodwill	829.97K	3.51M	2.38M	1.15M	2.03M	2.01M	1.8M	1.89M	1.86M	2M
Intangible Assets	4.34M	20.93M	13.91M	7.71M	11.52M	10.4M	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	3.27M	21.26M	170K	577K	5.28M	2.55M	7.21M
Total Assets+	46.98M	76.38M	78.39M	75.46M	102.5M	113.37M	664.17M	202.95M	435.56M	751.18M
Asset Turnover	0.06x	0.23x	0.72x	0.01x	0.01x	0.02x	0.00x	-	-	-
Asset Growth %	31.55%	62.58%	2.63%	-3.74%	35.84%	10.61%	485.82%	-69.44%	114.62%	72.46%
Total Current Liabilities+	13.62M	26.81M	16.88M	9.9M	19.89M	25.62M	38.78M	20.41M	41.73M	72.99M
Accounts Payable	1.13M	12.49M	5.8M	2.63M	6.14M	4.37M	355K	2.67M	4.64M	15.06M
Days Payables Outstanding	-	46.68K	84.95K	6.18K	-	-	51.54	474.86	112.76	50.73K
Short-Term Debt	0	0	0	632.64K	0	284.24K	19.77M	0	0	3.39M
Deferred Revenue (Current)	8.64M	-18.03M	0	1.17M	8.37M	7.94M	0	0	0	0
Other Current Liabilities	6.64M	20.04M	10.62M	2.45M	1.71M	5.31M	6.3M	9.5M	33.33M	54.54M
Current Ratio	3.06x	1.89x	3.63x	6.27x	3.34x	3.80x	16.93x	9.30x	10.15x	9.87x
Quick Ratio	3.05x	1.89x	3.63x	6.27x	3.93x	3.52x	16.93x	9.30x	10.15x	9.87x
Cash Conversion Cycle	-	-	-	-3.02K	-	-	-	-	-	-
Total Non-Current Liabilities+	37.73M	35.59M	5.71M	4.44M	3.15M	4.47M	498.73M	104.85M	5.08M	19.33M
Long-Term Debt	0	-17.21M	0	0	0	0	494.54M	100M	0	17.5M
Capital Lease Obligations	0	962K	0	318.56K	75K	1.25M	2.76M	3.29M	3.45M	12.99M
Deferred Tax Liabilities	706.22K	3.37M	2.2M	1.61M	0	0	0	0	0	0
Other Non-Current Liabilities	-39.87K	5.73M	3.28M	2.2M	2.51M	3.22M	1.43M	1.56M	1.63M	-11.63M
Total Liabilities	51.35M	62.4M	22.59M	14.34M	23.05M	30.09M	537.51M	125.26M	46.81M	92.32M
Total Debt+	0	0	0	699.64K	465K	2.78M	518.76M	106.1M	7.22M	20.89M
Net Debt	-35.08M	-28.45M	-35.23M	-49.26M	-65.95M	-69.01M	170.16M	34.67M	-97.64M	-204.38M
Debt / Equity	-	-	-	0.01x	0.01x	0.03x	4.10x	1.37x	0.02x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	0.41x	-
Net Debt / EBITDA	-	-	-4.80x	-	-	-	-	-	-5.59x	-
Interest Coverage	-28.84x	-22.18x	8.69x	-695.65x	-208.60x	-306.71x	-13.55x	-5.45x	0.04x	-
Total Equity+	-4.37M	13.98M	55.8M	61.12M	79.45M	83.28M	126.65M	77.69M	388.75M	658.86M
Equity Growth %	-114.51%	420.14%	299.18%	9.53%	30.01%	4.82%	52.07%	-38.66%	400.37%	69.48%
Book Value per Share	-0.07	0.21	0.65	1.86	1.14	0.90	0.66	0.13	0.54	0.88
Total Shareholders' Equity	-4.37M	13.98M	55.8M	61.12M	79.45M	83.28M	126.65M	77.69M	388.75M	658.86M
Common Stock	772.47K	1.04M	2.1M	3.47M	826K	980K	2.11M	7.02M	7.38M	7.75M
Retained Earnings	-92.21M	-114.51M	-99.8M	-97.61M	-214.74M	-299.55M	-378.33M	-993.26M	-1.21B	-2.29B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	25.74M	0	0	22.03M	-3.79M	-2.2M	-1.89M	-2.45M	-2.29M	-2.54M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jan 2017	Jan 2018	Jan 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	15.18M	-20.79M	-35.14M	-15.56M	-48.11M	-72.59M	-41.58M	-76.76M	-142.11M	-322.93M
Operating CF Margin %	526.93%	-118.84%	-62.3%	-2543.82%	-5594.3%	-4012.55%	-5904.06%	-	-	-
Operating CF Growth %	162.02%	-237.01%	-69.02%	55.71%	-209.1%	-50.87%	42.71%	-84.6%	-85.13%	-127.25%
Net Income	-32.13M	-15.42M	6.6M	-23.88M	-52.7M	-88.6M	-78.78M	-614.93M	-221.31M	-1.08B
Depreciation & Amortization	72.5K	348.2K	1.49M	1.39M	2M	2.46M	2.51M	2.05M	89K	-6.86M
Stock-Based Compensation	1.72M	2.27M	6.22M	542.05K	1.29M	9.47M	9.88M	14.11M	50.98M	732.42M
Deferred Taxes	4.66M	0	3	309.13K	583K	326K	0	0	0	0
Other Non-Cash Items	1.06M	3.47M	1.73M	5.12M	-385K	497K	14.12M	524.38M	12.66M	7.78M
Working Capital Changes	39.79M	-11.47M	-51.18M	955.98K	619K	-67K	8.62M	-2.37M	15.48M	23.32M
Change in Receivables	0	0	0	4.63M	212K	-1.14M	975K	4.53M	535K	0
Change in Inventory	0	0	0	-2	-6.61M	3.6M	0	0	0	0
Change in Payables	0	0	0	-997.71K	1.64M	-1.71M	-4.13M	2.26M	2.02M	11.36M
Cash from Investing+	-100K	-7.42M	-410.52K	-265.33K	-421K	-306K	-624K	-587.77M	-205.34M	-174.31M
Capital Expenditures	-110K	-678.01K	-163.94K	-265.33K	-421K	-306K	-624K	-128K	-139K	-657K
CapEx % of Revenue	3.82%	3.88%	0.29%	43.36%	48.95%	16.92%	88.6%	-	-	-
Acquisitions	0	-6.76M	-251.82K	-99.19K	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	10K	16.98K	5.25K	11.95K	0	0	-600	-474.79M	-15.01M	0
Cash from Financing+	516.23K	19.68M	43.85M	37.46M	50.55M	77.92M	620.24M	86.51M	381.23M	617.53M
Debt Issued (Net)	23K	-181.18K	-368.55K	0	0	0	520M	-24.69M	-100M	0
Equity Issued (Net)	0	1000K	1000K	0	1000K	1000K	0	1000K	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	493.23K	-7.05M	-1.21M	37.46M	551K	2.92M	100.24M	106.2M	3.33M	159.22M
Net Change in Cash	14.7M	-11.27M	8.86M	27.7M	2.58M	5.37M	576.82M	-577.18M	33.76M	120.39M
Free Cash Flow+	15.07M	-21.47M	-35.31M	-15.83M	-48.53M	-72.89M	-42.21M	-76.89M	-142.25M	-323.59M
FCF Margin %	523.11%	-122.72%	-62.59%	-2587.18%	-5643.26%	-4029.46%	-5992.66%	-	-	-
FCF Growth %	161.33%	-242.51%	-64.45%	55.16%	-206.58%	-50.2%	42.1%	-82.17%	-85%	-127.49%
FCF per Share	0.24	-0.33	-0.41	-0.48	-0.70	-0.79	-0.22	-0.12	-0.20	-0.43
FCF Conversion (FCF/Net Income)	-0.71x	0.73x	-3.56x	0.65x	0.91x	0.82x	0.53x	0.12x	0.64x	0.30x
Interest Paid	0	0	0	0	0	85K	0	10.65M	0	0
Taxes Paid	0	0	0	0	0	7K	0	52K	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-166.11%	-593.72%	28.3%	-40.86%	-74.98%	-108.89%	-75.05%	-601.85%	-94.9%	-206.1%
Return on Invested Capital (ROIC)	-	-	132.64%	-104.67%	-314.71%	-465.43%	-28.75%	-32.9%	0.12%	-163.41%
Gross Margin	100%	99.45%	99.96%	77.9%	100%	100%	-256.99%	-	-	-
Net Margin	-742.05%	-163.09%	17.5%	-3903.43%	-6127.56%	-4897.84%	-11185.94%	-	-	-
Debt / Equity	-	-	-	0.01x	0.01x	0.03x	4.10x	1.37x	0.02x	0.03x
Interest Coverage	-28.84x	-22.18x	8.69x	-695.65x	-208.60x	-306.71x	-13.55x	-5.45x	0.04x	-
FCF Conversion	-0.71x	0.73x	-3.56x	0.65x	0.91x	0.82x	0.53x	0.12x	0.64x	0.30x
Revenue Growth	124.82%	507.47%	222.45%	-98.92%	40.55%	110.35%	-61.07%	-100%	-	-

Summit Therapeutics Inc. (SMMT) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare SMMT vs Peers

vs BNTX

vs MRNA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Summit Therapeutics Inc. (SMMT) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare SMMT vs Peers

vs BNTX

vs MRNA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios